Related Experiment Video
Updated: Jun 19, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Identification of Target Genes Using Innovative Screening Systems
Keisuke Sugita1,2,3, Morito Kurata1,4
1Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
Abstract:
Advances in cancer biology have been achieved by the identification of oncogenes and tumor suppressor genes through the remarkable progression of next-generation sequencing. New techniques, such as single-cell analysis, help uncover cancer progression and heterogeneity. Reverse genetic screenings, including methods like random mutagenesis via retroviruses, transposons, RNA interference, and CRISPR, are useful for exploring gene functions and their roles in cancer. Especially in random mutagenesis, CRISPR screening and its modifications have recently emerged as powerful tools due to their comprehensiveness and simplicity in inducing genetic mutations. Initially, CRISPR screening focused on analyzing biological phenotypes in a cell population. It has since evolved to incorporate advanced techniques, such as combining single-cell and spatial analyses. These developments enable the investigation of cell-cell and spatial interactions, which more closely mimic In Vivo microenvironments, offering deeper insights into complex biological processes. These approaches allow for the identification of essential genes involved in cancer survival, drug resistance, and tumorigenesis. Together, these technologies are advancing cancer research and therapeutic development.
Insights
Next-generation sequencing and CRISPR screening advance cancer research by identifying key genes for survival and drug resistance. These powerful genetic tools, including single-cell and spatial analyses, offer deeper insights into tumor complexity and therapeutic development.
Area of Science:
- Genomics
- Cancer Biology
- Genetic Engineering
Background:
- Next-generation sequencing (NGS) has revolutionized cancer biology by identifying oncogenes and tumor suppressor genes.
- Single-cell analysis and reverse genetic screenings are crucial for understanding cancer progression and heterogeneity.
- CRISPR screening has become a powerful tool for functional genomics in cancer research due to its efficiency and simplicity.
Purpose of the Study:
- To explore the role of gene function in cancer using advanced genetic screening techniques.
- To investigate cancer progression, heterogeneity, and drug resistance mechanisms.
- To highlight the advancements in CRISPR screening and its integration with single-cell and spatial analyses for in vivo mimicry.
Main Methods:
- Utilizing reverse genetic screening methods, including random mutagenesis (retroviruses, transposons, RNA interference) and CRISPR.
- Employing CRISPR screening and its modifications for comprehensive genetic mutation induction.
- Integrating single-cell and spatial analyses with CRISPR screening to study cell-cell and spatial interactions.
Main Results:
- Identification of essential genes involved in cancer survival, drug resistance, and tumorigenesis.
- Enhanced understanding of cancer progression and heterogeneity through advanced screening techniques.
- CRISPR screening, especially when combined with single-cell and spatial analyses, provides deeper insights into in vivo microenvironments.
Conclusions:
- CRISPR screening and related technologies are significantly advancing cancer research.
- These genetic tools are vital for uncovering complex biological processes in cancer.
- The integration of various screening and analysis techniques accelerates the development of novel cancer therapeutics.
More Related Videos
Related Concept Videos
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
01:29Pharmacogenomics: Identification of New Drug Targets